Dosing Options and Flexibility Considerations for PD-1 Inhibitors

This discussion reviews the dosing flexibility available for PD-1 inhibitors used in advanced gastric and gastroesophageal junction (GEJ) cancers. The discussion outlines how approved agents can be administered on different schedules that align with patient needs and chemotherapy cycles. Nivolumab may be given every 2 or 4 weeks, while pembrolizumab offers both 3-week and 6-week dosing intervals. Tislelizumab, as studied in first-line gastric and GEJ adenocarcinoma, is administered every 3 weeks. These options allow clinicians to tailor treatment frequency based on clinical considerations such as patient travel constraints, clinic capacity, or preference for less frequent visits when appropriate. Importantly, dosing selection remains consistent with established pharmacokinetic and efficacy data for each agent. Overall, the segment emphasizes how validated dosing intervals support practical, patient-centered treatment planning in advanced gastric and GEJ cancers.